These trials completed more than 12 months ago and should have reported results.

These trials are not yet due to report results: some are ongoing, some completed within the past 12 months.

These trials have problematic data on the registry. Details why »

Status Trial ID Title Completion date Category
Reported results 2010-018580-42 Randomized, double-blind, placebo-controlled, parallel-group study of the safety and efficacy of imeglimin or placebo add-on therapy in type 2 diabetic subjects not adequately controlled by metformin ... 2011-07-14 due-trials
Reported results 2010-023915-33 Randomized, double-blind, placebo-controlled, parallel-group study of the safety and efficacy of imeglimin or placebo add-on therapy in type 2 diabetic subjects not adequately controlled by sitaglipti... 2012-06-14 due-trials
Reported results 2011-004086-32 Étude randomisée en double-aveugle versus placebo des effets de l’iméglimine sur la sécrétion d’insuline au cours d’un clamp hyperglycémique chez le sujet diabétique de type 2013-05-23 due-trials
Reported results 2012-004045-33 A dose-ranging, randomized, double-blind, placebo-controlled, parallel-group, multi-center study of the efficacy and safety of 4 doses of imeglimin after 24 weeks of treatment in subjects with type 2 ... 2014-07-10 due-trials
Reported results 2013-001539-35 A randomized, double-blind, placebo-controlled, parallel-group study of the efficacy and safety of one dose of imeglimin versus placebo after 18 weeks of treatment in subjects with type 2 diabetes mel... 2014-10-27 due-trials
Completed, but no date, and reported results Terminated 2016-003215-35 A phase 2a, randomised, double-blind, placebo-controlled, cross-over, single and multiple dose study to assess the effects of imeglimin on nicotine-induced endothelial dysfunction in young non-smoker ... bad-data
Completed, but no date Terminated 2021-006223-18 A randomized open-label Phase 2a study to assess the pharmacokinetics and pharmacodynamic parameters of PXL770 after 12 weeks of treatment in male subjects with adrenomyeloneuropathy (AMN) bad-data